INSM2
Insulinoma-associated protein 2
Also known as: IA-6, INSM2_HUMAN, Mlt1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96T92
- Gene
- INSM2
- Ensembl
- ENSG00000168348
- Chromosome
- 14
- Canonical length
- 566 aa
- Protein class
- Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
Predicted to enable DNA-binding transcription repressor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in negative regulation of transcription by RNA polymerase II; neuron differentiation; and regulation of cell cycle process. Predicted to be located in cytoplasm. Predicted to be part of transcription repressor complex. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
566 residues, UniProt reviewed canonical sequence.
>Q96T92|INSM2
1 MPRGFLVKRT KRTGGLYRVR LAERVFPLLG PQGAPPFLEE APSASLPGAE RATPPTREEP
61 GKGLTAEAAR EQSGSPCRAA GVSPGTGGRE GAEWRAGGRE GPGPSPSPSP SPAKPAGAEL
121 RRAFLERCLS SPVSAESFPG GAAAVAAFSC SVAPAAAPTP GEQFLLPLRA PFPEPALQPD
181 PAPLSAALQS LKRAAGGERR GKAPTDCASG PAAAGIKKPK AMRKLSFADE VTTSPVLGLK
241 IKEEEPGAPS RGLGGSRTPL GEFICQLCKE QYADPFALAQ HRCSRIVRVE YRCPECDKVF
301 SCPANLASHR RWHKPRPAAA NAATVSSADG KPPSSSSSSS RDSGAIASFL AEGKENSRIE
361 RTADQHPQAR DSSGADQHPD SAPRQGLQVL THPEPPLPQG PYTEGVLGRR VPVPGSTSGG
421 RGSEIFVCPY CHKKFRRQAY LRKHLSTHEA GSARALAPGF GSERGAPLAF ACPLCGAHFP
481 TADIREKHRL WHAVREELLL PALAGAPPET SGPSGPSDGS AQQIFSCKHC PSTFFSSPGL
541 TRHINKCHPS ESRQVLLLQM PLRPGCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against INSM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.66
- Highest tissue expression
- 2.5 nTPM
Expression across tissuesHPA
Tissue
- retina: 2.5 nTPM
- hypothalamus: 2 nTPM
- cerebral cortex: 1.5 nTPM
- basal ganglia: 1 nTPM
- midbrain: 0.6 nTPM
- testis: 0.6 nTPM
Single-cell type
- early primary spermatocytes: 5.1 nCPM
- rod photoreceptor cells: 4.2 nCPM
- cone photoreceptor cells: 4.1 nCPM
- retinal ganglion cells: 3.9 nCPM
- other brain neurons: 3 nCPM
- breast myoepithelial cells: 2.6 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- hypothalamus: 8.6 nTPM
- cerebral cortex: 5.9 nTPM
- pons: 5.5 nTPM
- thalamus: 4.5 nTPM
- basal ganglia: 3.4 nTPM
- white matter: 3.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about INSM2.
Disease | AutoantibodyPubMed
Conditions in which antibodies against INSM2 are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for INSM2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
25 publications
- Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY).
2015 · Diabetes Care · RCR 4.7 · 141 citations - The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study.
2010 · Diabetes Care · RCR 3.4 · 128 citations - Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes.
2012 · J Clin Endocrinol Metab · RCR 2.8 · 87 citations - Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials.
2010 · Diabetologia · RCR 1.9 · 75 citations - Identification of autoantibody-negative autoimmune type 2 diabetic patients.
2011 · Diabetes Care · RCR 1.7 · 64 citations
Show 20 more
- Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial.
2003 · Diabetes · RCR 1.6 · 74 citations - Models for predicting type 1 diabetes in siblings of affected children.
2006 · Diabetes Care · RCR 1.6 · 70 citations - T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes.
2007 · Diabetes · RCR 1.1 · 51 citations - Genetic Composition and Autoantibody Titers Model the Probability of Detecting C-Peptide Following Type 1 Diabetes Diagnosis.
2021 · Diabetes · RCR 1.1 · 18 citations - Type 1 diabetes-related autoimmune antibodies in women with gestational diabetes mellitus and the long-term risk for glucose intolerance.
2022 · Front Endocrinol (Lausanne) · RCR 0.8 · 7 citations - Autoantibodies against islet cell antigens in children with type 1 diabetes mellitus.
2018 · Oncotarget · RCR 0.6 · 12 citations - IA-2 autoantibody affinity in children at risk for type 1 diabetes.
2012 · Clin Immunol · RCR 0.6 · 19 citations - Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients.
2010 · Diabetologia · RCR 0.5 · 21 citations - Older age of childhood type 1 diabetes onset is associated with islet autoantibody positivity >30 years later: the Pittsburgh Epidemiology of Diabetes Complications Study.
2020 · Diabet Med · RCR 0.4 · 7 citations - Cord blood insulinoma-associated protein 2 autoantibodies are associated with increased risk of type 1 diabetes in the population-based Diabetes Prediction in Skåne study.
2015 · Diabetologia · RCR 0.3 · 10 citations - The expression of GADA, ZnT8A and IA-2A in patients with type 1 diabetes mellitus with thyroid disease and their correlation with thyroid autoantibodies.
2023 · Eur Rev Med Pharmacol Sci · RCR 0.3 · 2 citations - Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (pre)type 1 diabetes: association with IA-2 and islet cell autoantibodies.
2001 · Diabetes Care · RCR 0.3 · 14 citations - [Prevalence of type 1 diabetes-specific autoantibodies and of certain HLA patterns in celiac disease].
2003 · Dtsch Med Wochenschr · RCR 0.1 · 3 citations - Enterovirus Neutralizing Antibodies, Monocyte Toll Like Receptors Expression and Interleukin Profiles Are Similar Between Non-affected and Affected Siblings From Long-Term Discordant Type 1 Diabetes Multiplex-Sib Families: The Importance of HLA Background.
2020 · Front Endocrinol (Lausanne) · RCR 0.1 · 1 citations - Type 1 diabetes in a Nigerian family - occurrence in three out of four siblings: A case report.
2019 · World J Diabetes · RCR 0.1 · 1 citations - A Plasmon-Enhanced Fluorescence Protein Microchip with High-Sensitivity for Multiple Islet Autoantibodies Measurements in Autoimmune Diabetes Diagnosis.
2018 · J Biomed Nanotechnol · RCR 0 · 1 citations - UNVEILING LADA: PREVALENCE AND CHARACTERISTICS AMONG TYPE 2 DIABETIC PATIENTS IN PORT SUDAN, SUDAN.
2025 · Georgian Med News - A Japanese infant with fulminant type 1 diabetes with disease-sensitive CSAD polymorphism and HLA haplotype.
2025 · Clin Pediatr Endocrinol - GADA as a biomarker for type 1 diabetes.
2026 · Clin Chim Acta - Impact of Autoimmune Hypothyroidism and Celiac Disease on Progression to Diabetes in Individuals Positive for GAD65 or IA-2 Autoantibodies.
2026 · Diabetes Obes Metab
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.42
- gnomAD pLI
- 0.88
- gnomAD missense Z
- 0.78
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of transcription by RNA polymerase II
- neuron differentiation
- regulation of cell cycle process
Molecular functions
- DNA-binding transcription repressor activity, RNA polymerase II-specific
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads INSM2 as an antibody target. Whether an autoantibody or antibody against INSM2 could matter depends on whether native INSM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
INSM2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label INSM2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...